This Guide is part of WHO’s overall programme of work on Political Economy of Health Financing Reform: Analysis and Strategy to Support UHC. The impetus for this work came from demands for more concrete evidence, recognition and integration of political economy issues within
health financing, and... overall system, reform design and implementation processes. This Guide is complementary to WHO’s Health Financing Progress Matrix assessment, as well as Health Financing Strategy development guidance. In this way, it promotes an embedded political
economy analysis approach that can be used in conjunction with other health financing assessments and guidance. The political economy framework can also be extended and easily adapted to broader health policy reforms.
more
Questions concerning the relevance and reform of official development assistance (ODA), and how ODA and broader development finance could—or should—change to better reflect shifting demands are not new, with academics and policymakers suggesting a range of options for reform. In this background ...note, we briefly review the major reform proposals from 2009 onwards, highlighting the key issues underlying approaches to ODA reforms, and the main “types” of proposals typically put forward.
more
Frequent efforts to revise the official development assistance (ODA) accounting rules have raised important questions about the integrity and relevance of what currently “counts” as ODA spending. In this note, we outline a brief history of the evolution of the ODA accounting rules to date, highl...ighting how—and why—the ODA concept has changed since it emerged in 1969. Doing so provides a starting point for considering whether the current concept of ODA remains “fit for purpose” and whether, or how, the concept could reform to better meet current needs.
more
The UK could regain its leadershipin the provision of development assistance for healthunder the next government. But this doesn’t seem likely if the party manifestos are any guide.
The world is facing a sustainable development crisis. The 2024 Financing for Sustainable Development Report: Financing for Development at a Crossroads finds that financing challenges are at the heart of the crisis and imperil the SDGs and climate action. The window to rescue the SDGs and prevent a c...limate catastrophe is still open but closing rapidly. Financing gaps for sustainable development are large and growing – the estimates by international organizations and others are coalescing around $4 trillion additional investment needed annually for developing countries. This represents a more than 50% increase over the pre-pandemic estimates. Meanwhile, the finance divide has not been bridged, with developing countries paying around twice as much on average in interest on their total sovereign debt stock as developed countries. Many countries lack access to affordable finance or are in debt distress. Weak enabling environments are preventing progress. Average global growth has declined, while policy and regulatory frameworks still do not set appropriate incentives. Public budgets and spending is not fully aligned with SDGs. Private investors are not incentivised to invest enough in SDGs and climate action. The world is at a crossroads. This is the last chance to correct course if we want to achieve the SDGs by the 2030 deadline. Only an urgent, large-scale and sustainable investment push can help us achieve our global goals. Next year’s Fourth International Conference on Financing for Development in 2025 will be a once in 80-year opportunity to support coherent transformation of financing.
more
Le flyer „MMV Strategy“ présente la stratégie de la Medicines for Malaria Venture (MMV) pour lutter contre le paludisme. Il met en avant les objectifs clés de l'organisation, qui se concentre sur la recherche et le développement de nouveaux médicaments antipaludiques. Le document décrit le...s efforts pour améliorer l'accès aux traitements de qualité, soutenir les partenariats mondiaux, et accélérer l'innovation dans la lutte contre le paludisme, avec un accent particulier sur les populations à risque élevé.
more
The MSF malaria guidelines provide practical, evidence-based recommendations for diagnosing, treating, and preventing malaria, especially in low-resource settings. They cover uncomplicated and severe cases, recommend rapid tests and artemisinin-based therapies, and include special guidance for vulne...rable groups like children and pregnant women.
more
Malaria in pregnancy is a significant health problem in malaria-endemic areas. It not only causes substantial childhood morbidity and mortality but also increases the risks of adverse events for pregnant women and their developing fetuses. Most of the burden in these areas is due to infection with P...lasmodium falciparum. Artemisinin-based combination therapy (ACT) has been recommended as first-line treatment for uncomplicated P. falciparum malaria in all populations, including pregnant women in their second and third trimesters, since 2006. However, for women in their first trimester of pregnancy, WHO recommended as first-line treatment a combination of quinine and clindamycin.
Based on a review of the evidence conducted in 2022, WHO now recommends artemether–lumefantrine, the ACT with the most human safety data available, as the preferred treatment for uncomplicated P. falciparum malaria in the first trimester of pregnancy. This document presents all relevant evidence on the effects and safety in early pregnancy of artemisinins and partner medicines used in ACTs from both studies in experimental animals and observational studies in humans.
more
The WHO guidelines for malaria bring together the Organization’s most up-to-date recommendations for malaria in one user-friendly and easy-to-navigate online platform.
The WHO guidelines for malaria bring together the Organization’s most up-to-date recommendations for malaria in one user-frie...ndly and easy-to-navigate online platform. The Guidelines supersedes 2 previous WHO publications: the Guidelines for the treatment of malaria, third edition and the Guidelines for malaria vector control. Recommendations on malaria will continue to be reviewed and, where appropriate, updated based on the latest available evidence. Any updated recommendations will always display the date of the most recent revision in the MAGICapp platform. With each update, a new PDF version of the consolidated guidelines will also be available for download on the WHO website.
This version of the Guidelines includes an updated recommendation for malaria vaccines, new recommendations on the use of near-patients qualitative and semiquantitative G6PD tests to guide anti-relapse treatment of P. vivax and P. ovale, updated recommendations on primaquine and the recommendation on the use of tafenoquine. It replaces the versions published on 16 February 2021, 13 July 2021, 18 February 2022, 31 March 2022, 3 June 2022, 25 November 2022, 14 March 2023 and 16 October 2023.
more
Les Lignes directrices de l'OMS sur le paludisme rassemblent les recommandations les plus récentes de l'Organisation pour le paludisme dans une plateforme en ligne facile à utiliser et à naviguer.
Les Lignes directrices de l'OMS sur le paludisme remplacent 2 publications précédentes de l'OMS...: les Lignes directrices pour le traitement du paludisme, troisième édition et les Lignes directrices pour la lutte contre les vecteurs du paludisme. Les recommandations sur le paludisme continueront d'être examinées et, le cas échéant, mises à jour sur la base des dernières données disponibles. Toutes les recommandations mises à jour afficheront toujours la date de la révision la plus récente dans la plateforme MAGICapp. À chaque mise à jour, une nouvelle version PDF des lignes directrices unifiées sera également disponible en téléchargement sur le site Web de l'OMS.
more
Las Directrices de la OMS sobre la malaria reúnen las recomendaciones más actualizadas de la Organización acerca de la malaria (o paludismo) en una plataforma en línea fácil de usar y de navegar.
La primera versión de las Directrices es una recopilación de las recomendaciones existentes de... la OMS sobre la malaria y reemplaza a dos publicaciones anteriores de la OMS: las Directrices para el tratamiento del paludismo, tercera edición (en inglés unicamente), y las Directrices para el control de vectores del paludismo. Se seguirán revisando las recomendaciones sobre la malaria y, cuando proceda, se actualizarán en función de los últimos datos probatorios disponibles. Todas las recomendaciones actualizadas mostrarán siempre la fecha de la revisión más reciente en la plataforma MAGICapp. Con cada actualización, habrá también disponible en el sitio web de la OMS una nueva versión en PDF de las directrices unificadas que se podrá descargar.
Esta versión corresponde a la publicada en inglés el 13 de julio del 2021. La actualización se está traduciendo actualmente.
more
This WHO guidance outlines reactive strategies to interrupt malaria transmission in areas nearing elimination or to prevent re-establishment, triggered by confirmed cases.
The purpose of the guideline is to provide information to stakeholders on the necessary requirements for a complete prequalification dossier for insecticide-treated nets (ITNs). Its aim is to establish the baseline for dossier requirements which are necessary to assess ITN products for the purposes ...of prequalification, describe the data requirements for fulfilling each dossier module, and to provide standardized information for applicants and testing facilities generating data for ITN prequalification dossiers. The document is supported by implementation guidance documents which provide specific information and considerations for how applicants may approach the generation of supporting information and compilation of a complete product dossier.
more
2023 was another year of significant progress in the fight against HIV, tuberculosis (TB) and malaria. In countries where the Global
Fund invests, there has been a full recovery from the disruptive impact of the COVID-19 pandemic. The results we have achieved in the last year build on our extraord...inary track record of progress. Over the last two decades, our partnership has cut the combined death rate from AIDS, TB and malaria by 61%. As of the end of 2023, the Global Fund partnership has saved 65 million lives.
more
Depending on the health profile of the traveller, the type of travel to be undertaken, and the place of transit and destination, travellers may face various health risks during travel. The International travel and health collection is an update of International travel and health (2012) and serves as... an entry point for other World Health Organization (WHO) publications that provide further information. Its primary target audience is travel health practitioners and travel health professionals, who provide health advice to travellers on appropriate precautions to be taken to minimize any travel-related health risks in unfamiliar environments, before, during and after travel. The guidance may also be of interest to health authorities who intend to support travel health professionals in their jurisdiction or develop
health advice for their population. It may also be of interest to travellers who wish to obtain such information for themselves as well as those working in the travel industry, such as agents and organizers, airlines and shipping companies.
Module 3 outlines the clinical features, geographical distribution and chemoprophylaxis against malaria, as well as personal protection measures against mosquitoes that travellers should take during their journey and at destinations, and treatment for those who are infected.
more
Malaria remains a significant global health concern, with 249 million cases and 408,000 deaths reported in 2022, primarily in sub-Saharan Africa. The most vulnerable populations are children under five and pregnant women. Rapid and accurate diagnosis using microscopy or malaria rapid diagnostic test...s (mRDTs) is essential to ensure timely treatment, prevent severe disease and promote the rational use of antimalarial drugs. This UNICEF Technical Bulletin provides guidance on the procurement, quality assurance and selection of WHO-prequalified mRDTs, including considerations for areas with a high prevalence of pfhrp2/3 gene deletions. The bulletin also highlights UNICEF’s approach to sustainability, product verification and long-term arrangements with manufacturers, which ensure a reliable supply while supporting integrated child health management programmes. The bulletin serves as a valuable resource for countries, partners and programmes involved in the implementation of malaria case management and diagnostics.
more
Antimicrobial resistance (AMR) and malaria remain significant public health challenges in the WHO Eastern Mediterranean Region (EMR). In 2021, the region reported 1.7 million sepsis-related deaths, with 373,000 associated with bacterial AMR. High antibiotic consumption, particularly in high-income c...ountries, combined with rising usage in middle-income countries, has accelerated the emergence of drug-resistant infections. Malaria management is further complicated by biological threats, including vector insecticide resistance, PFHRP2/3 gene deletions, and antimalarial drug resistance, alongside insufficient trained personnel and limited molecular surveillance capacity. Effective strategies to address these challenges include strengthening regional and cross-border surveillance networks, designating WHO collaborating centers for molecular monitoring, enforcing national treatment policies, and raising public and healthcare provider awareness about rational antimalarial and antibiotic use. These measures, coupled with sustainable funding and enhanced therapeutic efficacy studies, are essential to reduce the development and spread of drug-resistant malaria and improve overall health outcomes in the EMR.
more